Desmopressin
Identification
- Name
- Desmopressin
- Accession Number
- DB00035 (BTD00112, BTD00061, BIOD00112, BIOD00061)
- Type
- Small Molecule
- Groups
- Approved
- Description
Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney [6]. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems.
Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH [2]. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate [3]. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate.
- Structure
- Synonyms
- 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
- 1-deamino-8-D-arginine vasopressin
- 1-desamino-8-D-arginine vasopressin
- dDAVP
- Desmopresina
- Desmopressine
- Desmopressinum
- Product Ingredients
Ingredient UNII CAS InChI Key Desmopressin acetate 1K12647SFC 62288-83-9 MLSVJHOYXJGGTR-IFHOVBQLSA-N Desmopressin acetate trihydrate XB13HYU18U 62357-86-2 YNKFCNRZZPFMEX-XHPDKPNGSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ddavp Solution .1 mg/mL Nasal Sanofi Aventis 1978-02-21 Not applicable US Ddavp Injection 4 ug/mL Intravenous Ferring Pharmaceuticals 1984-03-30 Not applicable US Ddavp Tablet .1 mg/1 Oral Sanofi Aventis 1995-09-06 Not applicable US Ddavp Tablet .1 mg/1 Oral Ferring Pharmaceuticals 1995-09-06 Not applicable US Ddavp Injection 4 ug/mL Intravenous Ferring Pharmaceuticals 1984-03-30 Not applicable US Ddavp Solution 4 ug/mL Intravenous Sanofi Aventis 1984-03-30 Not applicable US Ddavp Spray .1 ug/mL Nasal Ferring Pharmaceuticals 1978-02-21 Not applicable US Ddavp Spray .1 ug/mL Nasal Ferring Pharmaceuticals 1978-02-21 Not applicable US Ddavp Tablet .2 mg/1 Oral Sanofi Aventis 1995-09-06 Not applicable US Ddavp Tablet .2 mg/1 Oral Ferring Pharmaceuticals 1995-09-06 Not applicable US - Generic Prescription Products
- International/Other Brands
- Adiuretin (Ferring) / DesmoMelt (Ferring) / Minirin / Stimate
- Categories
- Amino Acids, Peptides, and Proteins
- Antidiuretic Agents
- Arginine Vasopressin
- Cardiovascular Agents
- Coagulants
- Factor VIII Activator
- Hematologic Agents
- Hemostatics
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Nerve Tissue Proteins
- Neuropeptides
- Oligopeptides
- Peptide Hormones
- Peptides
- Pituitary
- Pituitary and Hypothalamic Hormones and Analogues
- Pituitary Hormones
- Pituitary Hormones, Posterior
- Posterior Pituitary Lobe Hormones
- Proteins
- Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
- Vasopressin Analog
- Vasopressin and Analogues
- Vasopressins
- UNII
- ENR1LLB0FP
- CAS number
- 16679-58-6
- Weight
- Average: 1069.217
Monoisotopic: 1068.426954962 - Chemical Formula
- C46H64N14O12S2
- InChI Key
- NFLWUMRGJYTJIN-NXBWRCJVSA-N
- InChI
- InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
- IUPAC Name
- (2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide
- SMILES
- NC(=O)CC[[email protected]@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]@H](CCCNC(N)=N)C(=O)NCC(N)=O
Pharmacology
- Indication
Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).
Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).
Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).
- Structured Indications
- Pharmacodynamics
By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I [8]. Desmopressin demonstrates markedly diminished pressor activity. Desmopressin administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection [7].
- Mechanism of action
Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water [6].
Target Actions Organism AVasopressin V2 receptor agonistHuman AVasopressin V1a receptor Not Available Human AVasopressin V1b receptor Not Available Human - Absorption
Following nasal spray administration of 0.83 mcg and 1.66 mcg, median time to peak plasma concentrations (Tmax) was 0.25 and 0.75 hour, respectively [FDA Label]. The peak plasma concentration was approximately 4.00 (± 3.85) pg/mL and 9.11 (± 6.90) pg/mL, respectively [FDA Label]. The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1% [8].
The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours [9].
- Volume of distribution
The distribution volume of orally administered desmopressin is 0.2 – 0.32 l/kg [9]. It is not reported to cross the blood-brain barrier.
- Protein binding
Following radioiodination (125I) in the N-terminal, the fraction of plasma protein binding of desmopressin was reported to be 17.3 ± 1.5% in a pharmacokinetic study involving healthy subjects [5].
- Metabolism
In vitro, in human liver microsome preparations, it has been shown that no significant amount of desmopressin is metabolised in the liver and thus human liver metabolism in vivo is not likely to occur [9].
- Route of elimination
Desmopressin is mainly excreted in the urine. About 65% of the amount of desmopressin absorbed after oral administration could be recovered in the urine within 24 hours [9].
- Half life
Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours [FDA Label]. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment [FDA Label]. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours [9].
- Clearance
- Not Available
- Toxicity
Intravenous TDLo in humans is reported to be 0.3 µg/kg/10M [MSDS]. Desmopressin is associated with hyponatremia in case of overdose, which may require temporary or permanent discontinuation of the therapy depending on severity. The effects of hyponatremia include seizure, altered mental status (confusion, drowsiness or continuing headache), cardiac arrhythmias and worsening edema. Other signs of overdose may include oliguria and rapid weight gain due to fluid retention [FDA Label]. In case of overdose, reduce the dose or frequency of drug administration, or discontinue use if appropriate. Assessment of serum sodium and initiation of appropriate medical treatment is recommended.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desmopressin. Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Desmopressin. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin. Approved Alaproclate The risk or severity of adverse effects can be increased when Alaproclate is combined with Desmopressin. Experimental Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Desmopressin. Approved, Withdrawn Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin. Approved, Illicit Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Desmopressin. Experimental Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Desmopressin. Illicit Amineptine The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin. Illicit, Withdrawn Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin. Approved Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin. Approved Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Desmopressin. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Desmopressin. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin. Approved, Investigational Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Desmopressin. Experimental Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Desmopressin. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Desmopressin. Experimental Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin. Experimental, Illicit, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Desmopressin. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Desmopressin. Experimental Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin. Approved, Illicit, Vet Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmopressin. Experimental, Investigational Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin. Illicit, Investigational, Vet Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin. Approved, Investigational, Vet Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin. Approved, Investigational, Vet Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin. Approved Citalopram The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin. Approved Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin. Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin. Approved, Illicit Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin. Approved, Investigational Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin. Investigational Demeclocycline The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin. Approved, Investigational Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin. Approved, Investigational Dibenzepin The risk or severity of adverse effects can be increased when Dibenzepin is combined with Desmopressin. Experimental Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin. Approved, Vet Approved Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Desmopressin. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin. Experimental, Illicit Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin. Approved, Illicit Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin. Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin. Approved, Investigational DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin. Experimental Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin. Withdrawn Duloxetine The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Desmopressin. Investigational Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin. Approved Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin. Approved, Investigational Esmirtazapine The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin. Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Desmopressin. Experimental Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin. Approved, Illicit Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin. Approved, Investigational Etoperidone The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin. Withdrawn Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin. Illicit, Vet Approved Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Desmopressin. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Desmopressin. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin. Approved Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin. Approved, Illicit, Investigational, Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Desmopressin. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Desmopressin. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Desmopressin. Experimental Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin. Approved, Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desmopressin. Experimental Fluoxetine The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin. Approved, Vet Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin. Approved, Investigational Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin. Approved, Investigational Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Desmopressin. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin. Approved, Illicit, Investigational Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin. Investigational Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin. Approved, Illicit Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin. Approved, Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desmopressin. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin. Approved Indalpine The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin. Investigational, Withdrawn Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Desmopressin. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin. Withdrawn Iprindole The risk or severity of adverse effects can be increased when Iprindole is combined with Desmopressin. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin. Withdrawn Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin. Experimental Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin. Approved Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin. Approved Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin. Investigational Lithium The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin. Illicit Lofepramine The risk or severity of adverse effects can be increased when Lofepramine is combined with Desmopressin. Experimental Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Desmopressin. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin. Approved, Investigational Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin. Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin. Approved, Vet Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Desmopressin. Experimental Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin. Approved, Investigational, Withdrawn Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin. Approved, Investigational Mirtazapine The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Desmopressin. Experimental Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin. Approved Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin. Approved Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin. Approved, Vet Approved Nefazodone The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin. Approved, Withdrawn Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Nicomorphine is combined with Desmopressin. Experimental Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Desmopressin. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin. Investigational Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin. Approved Opipramol The risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin. Approved, Illicit Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin. Vet Approved Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin. Approved, Investigational, Vet Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin. Approved, Withdrawn Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin. Approved Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Desmopressin. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin. Approved, Vet Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Desmopressin. Experimental Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Desmopressin. Experimental Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin. Approved, Investigational Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin. Approved, Investigational Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Desmopressin. Experimental Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Desmopressin. Experimental, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Desmopressin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Desmopressin. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Desmopressin. Experimental Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin. Approved PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin. Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin. Approved Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin. Approved, Experimental, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin. Approved, Investigational, Withdrawn Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin. Approved Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Desmopressin. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Desmopressin. Investigational Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin. Investigational Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Desmopressin. Experimental Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desmopressin. Investigational Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Desmopressin. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin. Approved Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin. Approved, Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin. Approved Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Desmopressin. Experimental Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin. Approved Tolvaptan The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin. Approved, Investigational Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Desmopressin. Experimental Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin. Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin. Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin. Approved, Investigational, Withdrawn Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin. Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin. Approved, Investigational, Withdrawn Zimelidine The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin. Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.
US5674850- General References
- Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629]
- Richardson DW, Robinson AG: Desmopressin. Ann Intern Med. 1985 Aug;103(2):228-39. [PubMed:3893256]
- Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8. [PubMed:18690973]
- Agerso H, Seiding Larsen L, Riis A, Lovgren U, Karlsson MO, Senderovitz T: Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x. [PubMed:15373927]
- Lundin S, Broeders A, Melin P: Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin Endocrinol (Oxf). 1993 Sep;39(3):369-74. [PubMed:8222299]
- 32. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 399-400). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
- DDVAP Nasal Spray FDA Label [Link]
- Stimate (desmopressin acetate) nasal spray FDA Label [Link]
- UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets [Link]
- External Links
- Human Metabolome Database
- HMDB0014260
- KEGG Drug
- D00291
- KEGG Compound
- C06944
- ChemSpider
- 10481973
- BindingDB
- 50205291
- ChEBI
- 4450
- ChEMBL
- CHEMBL376685
- Therapeutic Targets Database
- DNC000526
- PharmGKB
- PA449237
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Desmopressin
- ATC Codes
- H01BA02 — Desmopressin
- AHFS Codes
- 68:28.00 — Pituitary
- FDA label
- Download (1.22 MB)
- MSDS
- Download (26.2 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Bedford laboratories div ben venue laboratories inc
- Hospira inc
- Teva parenteral medicines inc
- Ferring pharmaceuticals inc
- Bausch and lomb pharmaceuticals inc
- Apotex inc richmond hill
- Csl behring llc
- Apotex inc etobicoke site
- Teva pharmaceuticals usa
- Watson laboratories inc
- Packagers
- Amerisource Health Services Corp.
- Apotex Inc.
- Arcola Laboratories
- Bachem Inc.
- Barr Pharmaceuticals
- Bausch & Lomb Inc.
- CSL Behring LLC
- Ferring Pharmaceuticals Inc.
- Hospira Inc.
- Kaiser Foundation Hospital
- Pharmacy Service Center
- Physicians Total Care Inc.
- Promex Medical Inc.
- Rechon Life Science AB
- Sanofi-Aventis Inc.
- Sicor Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Injection Intravenous 4 ug/mL Spray Nasal .1 ug/mL Liquid Intramuscular; Intravenous; Subcutaneous 4 mcg Tablet, orally disintegrating Sublingual 120 mcg Tablet, orally disintegrating Sublingual 240 mcg Tablet, orally disintegrating Sublingual 60 mcg Solution Nasal .1 mg/mL Solution Nasal 0.1 mg Aerosol, metered Nasal 10 mcg Tablet Oral 0.1 mg Tablet Oral 0.2 mg Injection, solution Intravenous; Subcutaneous 4 ug/mL Injection, solution Intravenous; Subcutaneous 40 ug/10mL Solution Intravenous 4 ug/mL Spray Nasal .1 mg/mL Spray Nasal 10 ug/1 Spray Nasal 10 ug/.1mL Tablet Oral .1 mg/1 Tablet Oral .2 mg/1 Spray, metered Nasal 10 mcg Tablet, orally disintegrating Sublingual 25 mcg Tablet, orally disintegrating Sublingual 50 mcg Spray, metered Nasal .83 ug/1 Spray, metered Nasal 1.66 ug/1 Liquid Intravenous; Subcutaneous 15 mcg Spray Nasal 150 mcg Spray, metered Nasal 1.5 mg/mL - Prices
Unit description Cost Unit Stimate 1.5 mg/ml nasal spray 334.2USD ml Ddavp 0.01% nasal spray 50.76USD ml Ddavp 4 mcg/ml ampul 43.27USD ml Desmopressin 0.1 mg/ml spray 39.6USD ml Ddavp 0.1 mg/ml Solution 21.26USD ml Octostim 150 mcg/dose Metered Dose Spray 17.39USD dose Ddavp 4 mcg/ml 11.33USD ml Desmopressin ac 4 mcg/ml amp 7.28USD ml Desmopressin ac 4 mcg/ml vial 7.08USD ml Ddavp 0.2 mg tablet 6.43USD tablet Ddavp 0.1 mg tablet 4.47USD tablet Desmopressin acetate 0.2 mg tablet 4.44USD tablet Desmopressin acetate 0.1 mg tablet 3.08USD tablet Ddavp 0.2 mg Tablet 2.98USD tablet Ddavp 10 mcg/dose Metered Dose Spray 2.13USD dose Apo-Desmopressin 0.2 mg Tablet 1.67USD tablet Novo-Desmopressin 0.2 mg Tablet 1.67USD tablet Pms-Desmopressin 0.2 mg Tablet 1.67USD tablet Ddavp 0.1 mg Tablet 1.49USD tablet Apo-Desmopressin 10 mcg/dose Metered Dose Spray 1.48USD dose Apo-Desmopressin 0.1 mg Tablet 0.83USD tablet Novo-Desmopressin 0.1 mg Tablet 0.83USD tablet Pms-Desmopressin 0.1 mg Tablet 0.83USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7022340 No 2003-04-30 2023-04-30 US US5500413 No 1993-06-29 2013-06-29 US CA2484724 No 2007-01-16 2023-05-07 Canada CA2486833 No 2005-08-02 2024-04-30 Canada US9539302 No 2010-06-15 2030-06-15 US US7799761 No 2004-09-26 2024-09-26 US US7405203 No 2003-05-06 2023-05-06 US US7579321 No 2003-05-06 2023-05-06 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.11 mg/mL ALOGPS logP -1 ALOGPS logP -6.1 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 9.5 ChemAxon pKa (Strongest Basic) 11.77 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 15 ChemAxon Hydrogen Donor Count 14 ChemAxon Polar Surface Area 435.41 Å2 ChemAxon Rotatable Bond Count 19 ChemAxon Refractivity 279.78 m3·mol-1 ChemAxon Polarizability 104.7 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.7979 Blood Brain Barrier - 0.8866 Caco-2 permeable - 0.7612 P-glycoprotein substrate Substrate 0.8242 P-glycoprotein inhibitor I Non-inhibitor 0.7864 P-glycoprotein inhibitor II Non-inhibitor 0.9237 Renal organic cation transporter Non-inhibitor 0.5915 CYP450 2C9 substrate Non-substrate 0.7833 CYP450 2D6 substrate Non-substrate 0.7901 CYP450 3A4 substrate Non-substrate 0.5497 CYP450 1A2 substrate Non-inhibitor 0.8383 CYP450 2C9 inhibitor Non-inhibitor 0.7906 CYP450 2D6 inhibitor Non-inhibitor 0.8735 CYP450 2C19 inhibitor Non-inhibitor 0.765 CYP450 3A4 inhibitor Non-inhibitor 0.7663 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9331 Ames test Non AMES toxic 0.6679 Carcinogenicity Non-carcinogens 0.8428 Biodegradation Not ready biodegradable 0.9445 Rat acute toxicity 2.7183 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.83 hERG inhibition (predictor II) Inhibitor 0.6036
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Cyclic peptides / Arginine and derivatives / Proline and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / Pyrrolidinecarboxamides / N-acylpyrrolidines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives show 14 more
- Substituents
- Alpha-oligopeptide / Cyclic alpha peptide / Arginine or derivatives / N-acyl-alpha amino acid or derivatives / Proline or derivatives / Macrolactam / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / N-acylpyrrolidine show 30 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Vasopressin receptor activity
- Specific Function
- Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
- Gene Name
- AVPR2
- Uniprot ID
- P30518
- Uniprot Name
- Vasopressin V2 receptor
- Molecular Weight
- 40278.57 Da
References
- Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325]
- Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- General Function
- Vasopressin receptor activity
- Specific Function
- Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
- Gene Name
- AVPR1A
- Uniprot ID
- P37288
- Uniprot Name
- Vasopressin V1a receptor
- Molecular Weight
- 46799.105 Da
References
- Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046]
- Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321]
- Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254]
- Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- General Function
- Vasopressin receptor activity
- Specific Function
- Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
- Gene Name
- AVPR1B
- Uniprot ID
- P47901
- Uniprot Name
- Vasopressin V1b receptor
- Molecular Weight
- 46970.345 Da
References
- Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
- Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638]
- Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:16